<DOC>
	<DOCNO>NCT01823679</DOCNO>
	<brief_summary>Phase 2 evaluation capecitabine patient advance recurrent squamous cell carcinoma skin .</brief_summary>
	<brief_title>Capecitabine Treating Patients With Advanced Recurrent Squamous Cell Carcinoma Skin</brief_title>
	<detailed_description>Participants receive 500 mg/m² capecitabine orally ( PO ) twice daily ( BID ) day 1 14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 2 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>INCLUSION CRITERIA Squamous cell carcinoma skin `` unknown primary lesion '' time diagnosis metastatic disease present history plausible primary skin site remove past . Example : squamous cell carcinoma neck parotid lymph node identifiable mucosal primary history removal one early stage squamous cell carcinoma skin anatomically relevant lymphatic drainage region would eligible Measurable disease , define least 1 lesion accurately measure least 1 dimension ≥ 10 mm compute tomography ( CT ) scan ; magnetic resonance imaging ( MRI ) ; caliper clinical exam Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ( Karnofsky ≥ 60 % ) Life expectancy great 3 month Absolute neutrophil count ≥ 1,000/mcL Platelets ≥ 100,000/mcL Total bilirubin Within normal institutional limit OR ≤ 2 x upper limit normal ( ULN ) participant Gilbert 's syndrome ( elevate unconjugated bilirubin decrease UDP glucuronosyltransferase 1 family , polypeptide A1 [ UGT1A1 ] activity ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) ≤ 2.5 x institutional ULN 5 X ULN know cause liver metastasis Creatinine OR &lt; 1.3 mg/dL OR Creatinine clearance ≥ 30 mL/min/1.73 m2 patient creatinine level institutional normal ( Note creatinine clearance 30 49 mg/dL necessitate dose modification ) For participant history coronary artery disease ( CAD ) /myocardial infarction ( MI ) congestive heart failure ( CHF ) , ejection fraction ( EF ) ≥ 50 % multigated acquisition ( MUGA ) echocardiogram ( exception PI discretion ) EXCLUSION CRITERIA Prior treatment systemic capecitabine prodrugs Prior treatment systemic fluorouracil ( 5FU ) prodrugs ( prior topical treatment 5FU permit recovered toxicity &gt; grade 1 , least 5 halflives last systemically administer agent pass ) Receiving investigational agent anticancer treatment Candidates curative locoregional treatment ( patient recurrent locoregional disease follow surgery and/ radiation resection unacceptably morbid unlikely curative eligible ) History allergic reaction attribute compound similar chemical biologic composition capecitabine Uncontrolled concurrent illness include , limited : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement Pregnant Lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>